“Initial results show promising neuron spike detection,” Musk said on X on Monday.

The US Food and Drug Administration had given the company clearance in 2023 to conduct its first trial to test its implant on humans.

The first product from Neuralink would be called Telepathy, Musk said in a separate post on X.

The startup’s PRIME Study is a trial for its wireless brain-computer interface to evaluate the safety of the implant and surgical robot.

The study will assess the functionality of the interface, which enables people with quadriplegia or paralysis of all four limbs to control devices with their thoughts, according to the company’s website.

Neuralink opened the study trial for recruitment last September.

The startup did not immediately respond to a Reuters request for further details.

Neuralink has faced calls for scrutiny regarding its safety protocols.

Reuters reported earlier this month that the company was fined for violating US Department of Transportation (DOT) rules regarding the movement of hazardous materials.

Last November, four US lawmakers asked the US Securities and Exchange Commission to investigate whether Musk committed securities fraud by allegedly misleading investors about the safety of a brain implant being developed by Neuralink.

Source | AAP